A Phase 2 interventional study of temozolomide in Breast Neoplasm, Brain Neoplasm and Second Neoplasm, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-14.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing temozolomide in Breast Neoplasms — none open to participants now, none under way, none of them phase 3. Temozolomide · Breast Neoplasms.
Among the 10 studies testing temozolomide in Breast Neoplasms, this one is one of 2 that started in 2008, is one of 7 in phase 2, and was the 3rd registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →None of the 10 studies testing temozolomide in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →
Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8
First in 1998; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 30 across the 9 interventional studies. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 10 have an industry lead sponsor. The 9 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
41 studies in Breast Neoplasms by Merck & Co., Inc: 5 open now, 8 under way, 5 of them phase 3. Of 31 finished, 16 (52%) have results posted.
Among the 41 studies in Breast Neoplasms by Merck & Co., Inc, this one is the 35th largest by enrollment of the 39 interventional ones that give a count, is one of 6 that started in 2008, is one of 17 in phase 2, and was the 10th registered.
Merck & Co., Inc’s Breast Neoplasms studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing temozolomide in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 41 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether temozolomide can be used as a prophylaxis against brain recurrence in participants with metastatic breast cancer.
Breast cancer is the second most common cause of brain metastases. Overall survival after the development of brain metastases tends to be poor (6-8 months). Over-expression of Human Epidermal Growth Factor Receptor 2 (HER-2/neu), negative estrogen receptor, and young age at diagnosis seem to be indicators of high risk for brain metastases. Temozolomide may be a good candidate for prophylactic chemotherapy because of its ability to cross the blood-brain-barrier, achieving high concentrations in the central nervous system (CNS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: temozolomide
Capsules to equal 75 mg/m\^2, orally, daily for 6 weeks, in 3 eight-week cycles
Percent of Participants With Recurrence of Brain Metastases
The analysis could not be performed due to low enrollment.
Time frame: 1 Year
Number of Days With Progression-free Survival (PFS)
PFS was defined as the time interval from randomization to objective tumor progression or death from any cause. The analysis could not be performed due to low enrollment.
Time frame: 24, 38, and 52 weeks
Number of Days With Disease-free Survival (DFS)
DFS was defined as the time interval from randomization to any relapse (loco-regional, contra-lateral, and/or distant). The analysis could not be performed due to low enrollment.
Time frame: 24, 38, and 52 weeks
Number of Days With Distant Disease-free Survival (DDFS)
DDFS was defined as the time interval from randomization to only distant metastases (for example, bone, visceral organ, brain). The analysis could not be performed due to low enrollment.
Time frame: 24, 38, and 52 weeks
Number of Days With Brain Recurrence-free Survival (BRFS)
BRFS was defined as the time interval from randomization to the appearance of brain metastases. The analysis could not be performed due to low enrollment.
Time frame: 24,38, and 52 weeks
Number of Days on Temozolomide Treatment
This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.
Time frame: Baseline to 24 Weeks
Total Dose of Temozolomide Taken
This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.
Time frame: Baseline to 24 Weeks
Number of Participants Who Had at Least One Dose Reduction During Treatment
This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.
Time frame: Baseline to 24 Weeks
Number of Participants Who Had at Least One Treatment Omission During Treatment
This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.
Time frame: Baseline to 24 Weeks
Number of Participants Who Completed the Third Cycle of Treatment
This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.
Time frame: Baseline to 24 Weeks
| Milestone | Temozolomide | Observational |
|---|---|---|
| Started | 3 | 3 |
| Completed | 2 | 3 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
The analysis could not be performed due to low enrollment.
No measurements were reported for this outcome.
PFS was defined as the time interval from randomization to objective tumor progression or death from any cause. The analysis could not be performed due to low enrollment.
No measurements were reported for this outcome.
DFS was defined as the time interval from randomization to any relapse (loco-regional, contra-lateral, and/or distant). The analysis could not be performed due to low enrollment.
No measurements were reported for this outcome.
DDFS was defined as the time interval from randomization to only distant metastases (for example, bone, visceral organ, brain). The analysis could not be performed due to low enrollment.
No measurements were reported for this outcome.
BRFS was defined as the time interval from randomization to the appearance of brain metastases. The analysis could not be performed due to low enrollment.
No measurements were reported for this outcome.
This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.
| Days | Temozolomide |
|---|---|
| Number of Days on Temozolomide Treatment | 75 ± 65.82 |
This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.
| Milligrams | Temozolomide |
|---|---|
| Total Dose of Temozolomide Taken | 9791.9 ± 8732.0 |
This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.
| Participants | Temozolomide |
|---|---|
| Number of Participants Who Had at Least One Dose Reduction During Treatment | 3 |
This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.
| Participants | Temozolomide |
|---|---|
| Number of Participants Who Had at Least One Treatment Omission During Treatment | 2 |
This outcome measure was only applicable to the temozolomide arm; the observation arm was therefore not analyzed.
| Participants | Temozolomide |
|---|---|
| Number of Participants Who Completed the Third Cycle of Treatment | 2 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Temozolomide | — | 0/3 (0%) | 2/3 (66.7%) |
| Observational | — | 0/3 (0%) | 2/3 (66.7%) |
| Event | Temozolomide | Observational |
|---|---|---|
| NauseaGastrointestinal disorders | 2/3 | 0/3 |
| DiarrhoeaGastrointestinal disorders | 1/3 | 0/3 |
| VomitingGastrointestinal disorders | 1/3 | 0/3 |
| AstheniaGeneral disorders | 1/3 | 0/3 |
| Chest painGeneral disorders | 0/3 | 1/3 |
| Influenza like illnessGeneral disorders | 1/3 | 0/3 |
| PyrexiaGeneral disorders | 1/3 | 0/3 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/3 | 0/3 |
| InsomniaPsychiatric disorders | 1/3 | 0/3 |
| Vulvovaginal drynessReproductive system and breast disorders | 0/3 | 1/3 |
| Age, Categorical(Participants) | Temozolomide | Observational | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 3 | 6 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Temozolomide | Observational | Total |
|---|---|---|---|
| Female | 3 | 3 | 6 |
| Male | 0 | 0 | 0 |
| Region of Enrollment(participants) | Temozolomide | Observational | Total |
|---|---|---|---|
| Italy | 3 | 3 | 6 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
No publications or documents are linked to this record.
Ran from Oct 2008 to primary completion in Jun 2010, 20 months.
Results were first posted in Jul 2011, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Temozolomide